Patient Travel Concerns After Treatment with ¹⁷⁷Lu-DOTATATE

J Nucl Med. 2020 Apr;61(4):496-497. doi: 10.2967/jnumed.120.243238. Epub 2020 Mar 13.

Authors

Ayşe Tuba Kendi¹, Josh A Mailman², Boris G Naraev³, David J Mercer⁴, James K Underwood⁵, Thorvardur R Halfdanarson⁶

Affiliations

¹ Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, Minnesota kendi.ayse@mayo.edu.
² NorCal CarciNET Community, Oakland, California.
³ Banner M.D. Anderson Cancer Center, Gilbert, Arizona.
⁴ Los Alamos National Laboratory, Los Alamos, New Mexico.
⁵ Mayo Clinic Radiation Safety, Rochester, Minnesota; and.
⁶ Mayo Clinic Cancer Center, Rochester, Minnesota.

PMID: 32169915
DOI: 10.2967/jnumed.120.243238

No abstract available

MeSH terms

Humans
Octreotide / adverse effects
Octreotide / analogs & derivatives*
Octreotide / therapeutic use
Organometallic Compounds / adverse effects*
Organometallic Compounds / therapeutic use
Radiation Monitoring
Safety*
Travel*

Substances

Organometallic Compounds
lutetium Lu 177 dotatate
Octreotide